Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
  • TickerIPN
  • ISINFR0010259150
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Pierre Vaurice

IPSEN - Un risk/reward attractif (+)

IPSEN - Un risk/reward attractif (+)

GlobalData Department

Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The ...

Eric Le Berrigaud

IPSEN - BUY | EUR164(+34%) Cabometyx still growing steadily in the

IPSEN - BUY | EUR164(+34%) Cabometyx still growing steadily in the US 12% sequential growth for Cabometyx in the US in Q3 Exelixis suggests significant overlap between RCC and HCC A triplet combination in mRCC about to start phase III trial Cabometyx still in a relatively comfortable seat

Jérôme VINERIER

Short term view - IPSEN : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €116.00. The bearish trend would be challenged above €142.10.

Eric Le Berrigaud

Ipsen: Exelixis’ Q2 figures: Cabometyx continues to grow, with plus and minus

Brief Comment - Ipsen: (BUY, Fair Value EUR150 (+6%)) Exelixis’ Q2 figures: Cabometyx continues to grow, with plus and minus

Jean Raoul-Duval, CFA

Ipsen : 2017 looks promising, after a record year in 2016

We have a stable credit opinion on the issuer. Ipsen had a record year in 2016, marked by strong sales growth in its specialty care division, driven by: 1. Somatuline’s commercial success, particularly in the US, and 2. gradual recovery in Primary care through its shift towards an OTx model. Despite investments to support the launch of Cabometyx®, profitability also improved in 2016. Ipsen is adopting a resolutely optimistic tone for the current year, expecting robust growth on the back of numerous ongoing developments. In addition, Ipsen has enriched its pipeline in Oncology and Neurosciences...

Jean Raoul-Duval, CFA

Ipsen : Un exercice 2017 prometteur, après une année 2016 record

Nous avons un avis crédit Stable sur l’émetteur. Ipsen a réalisé une année 2016 record, marquée par la forte croissance des ventes de sa division Médecine de Spécialité portée par : 1. le succès commercial de Somatuline notamment aux US, et 2. le redressement progressif de l’activité Médecine Générale grâce à son repositionnement vers un modèle OTx. Malgré les investissements consentis pour le lancement de Cabometyx®, la rentabilité a également progressé en 2016. Ipsen adopte un ton résolument optimiste pour cette année, attendue en forte croissance grâce aux nombreux développements en cours. ...

Pierre Vaurice

IPSEN - Un risk/reward attractif (+)

IPSEN - Un risk/reward attractif (+)

Eric Le Berrigaud

IPSEN - BUY | EUR164(+34%) Cabometyx still growing steadily in the

IPSEN - BUY | EUR164(+34%) Cabometyx still growing steadily in the US 12% sequential growth for Cabometyx in the US in Q3 Exelixis suggests significant overlap between RCC and HCC A triplet combination in mRCC about to start phase III trial Cabometyx still in a relatively comfortable seat

Pierre Vaurice

IPSEN Turnover Q3 2018 (=). Absolutely in line

IPSEN Turnover Q3 2018 (=). Absolutely in line

Christophe-Raphaël Ganet

Ipsen : Q3 2018 sales in line and solid – Confirmation of full-year targets – No change to estimates

>Q3 2018: +18.3% and +20.2% l-f-l. - Ipsen’s Q3 2018 revenues reached € 555.9m (+18.3% and +20.2% excl. forex), buoyed by growth of 24.2% l-f-l in sales of speciality medicine (strong momentum for Somatuline® and Dysport®, and the continued ramp-up of Cabometyx® and Onivyde®).The forex effect is still present (-2 pts) but less marked than in H1 (-5 pts).Guidance is confirmed (group sales growth of over 19.0% and an operating margin of activities of around 29...

Christophe-Raphaël Ganet

Ipsen : CA T3 2018 conforme et solide – Confirmation des objectifs annuels – Pas de modification des estimations

>T3 2018: +18.3% et +20.2% lfl - Au T3, les revenus d’Ipsen ont atteint 555.9 M€ (+18.3% et +20.2% hors FX), tirés par la croissance de 24,2% lfl des ventes de Médecine de Spécialité (la forte dynamique de Somatuline® et Dysport®, et poursuite du ramp-up de Cabometyx® et d’Onivyde®).Les effets devises sont encore présents (-2 pts) mais encore moins marqués qu’au S1 (-5 pts).Les guidances sont confirmées (croissance des ventes du Groupe de plus de 19,0%1 et u...

1 director bought

A director at Ipsen bought 680 shares at 147.054EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members ...

Alexandre Iatrides ...
  • Alfred Glaser
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Johanna Jourdain
  • Louis Boujard
  • Matthias Desmarais
  • Nicolas David
  • Philippe Ourpatian
  • Roland Pfaender
  • Stephane Houri
  • Veysel Taze

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/25/2018

With 2018e FCF (£ 450m +/- £ 100m before restructuring costs) expected to reflect a significant upturn from the low point of 2016 (£ 100m), the group’s medium-term target FCF of £ 1.8bn appears realistic. On this basis, we value the group at 1,120p per share and we are upgrading our recommendation from Neutral to Buy. Cf report published yesterday night. - ...

Alexandre Iatrides ...
  • Alfred Glaser
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Johanna Jourdain
  • Louis Boujard
  • Matthias Desmarais
  • Nicolas David
  • Philippe Ourpatian
  • Roland Pfaender
  • Stephane Houri
  • Veysel Taze

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/10/2018

Avec un FCF 2018 (450 M£ +/- 100 M£ avant coût des restructurations) attendu en fort redressement par rapport au plus bas de 2016 (100 M£), l’objectif affiché par le groupe d’un FCF à 1.8 Md£ à moyen terme semble réaliste. Sur cette base, nous valorisons le groupe à 1 120 p par action et relevons notre recommandation de Neutre à Achat. - Cf étude publiée hier soir. - ...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

Nurhayati Wan

Ipsen SA

Nurhayati Wan

Ipsen SA

Nurhayati Wan

Ipsen SA

null

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GlobalData Department

Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The ...

Esther Bouguet

Proxy Report - 30/05/2018

Board of directors (resolutions 4 to 9) The independence rate of the Board amounts to only 38.5%. Each of the three largest shareholders should have at least one representative regardless of the board's independence. Accordingly, we recommend that shareholders approve the re-election of Anne Beaufour but not Philippe Bonhomme. A new member, Paul Sekhri, is chairman of two listed companies and member of the Board of two others listed companies. Therefore, we have concerns about his time commitment. Remuneration (resolutions 10 to 13) The lack of disclosure of the achievement rates of each cr...

Charles Pinel

Proxy Report - 30/05/2018

Le conseil n'est pas majoritairement composé de membres libres de conflits d'intérêts. La politique de vote de Proxinvest accepte la présence au conseil des principaux actionnaires quelque soit l'indépendance du conseil. Par conséquent, nous recommandons l'approbation du renouvellement d'Anne Beaufour, actionnaire principal de la société via la société Mayroy, mais la nomination de Philippe Bonhomme, jusqu'alors représentant de Mayroy au conseil, ne pourra être soutenue. Par ailleurs, un des deux nouveaux membres indépendants - Paul Sekhri - détient un nombre de mandats trop important pour êtr...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Jérôme VINERIER

Short term view - IPSEN : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €116.00. The bearish trend would be challenged above €142.10.

Jérôme VINERIER

Analyse court terme - IPSEN : Les prix baissent.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 116,00 €. La tendance baissière serait remise en cause au-dessus de 142,10 €.

Jérôme VINERIER

Short term view - IPSEN : The trend is bearish.

The trend is bearish. The movement goes on. The next target is at €116.00, then €103.90. Passing €142.10 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - IPSEN : La tendance est baissière.

La tendance est baissière. Le mouvement se poursuit. Le prochain objectif est à 116,00 €, puis 103,90 €. Le franchissement de 142,10 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Analyse moyen terme - IPSEN : La baisse récente gagne en vigueur.

La tendance est haussière. La baisse récente gagne en vigueur. Le prochain support est à 115,64 €. La tendance serait remise en cause par la rupture de 96,60 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch